Regulation of T-cell survival and mitochondrial homeostasis by TSC1

European Journal of Immunology

Volumn 41, Issue 11, 2011, Pages 3361-3370

  O'Brien, Thomas F ^a   Gorentla, Balachandra K ^a   Xie, Danli ^a,b   Srivatsan, Sruti ^a   Mcleod, Ian X ^a   He, You Wen ^a   Zhong, Xiao Ping ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cell survival; Mammalian target of rapamycin; Signal transduction; T cells; Tuberous sclerosis complex

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; REGULATOR PROTEIN; TUBERIN; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL LINEAGE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; HOMEOSTASIS; IMMUNOREGULATION; LYMPHOCYTE COUNT; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; APOPTOSIS; CELL LINE; CELL SEPARATION; CELL SURVIVAL; FLOW CYTOMETRY; HOMEOSTASIS; IMMUNOBLOTTING; MICE; MICE, KNOCKOUT; MICROSCOPY, FLUORESCENCE; MITOCHONDRIA; PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS;

EID: 80054721266     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201141411     Document Type: Article

References (40)

1. Stanfel, M. N., Shamieh, L. S., Kaeberlein, M. and Kennedy, B. K., The TOR pathway comes of age. Biochim. Biophys. Acta 2009. 1790: 1067-1074.
2. Guertin, D. A. and Sabatini, D. M., Defining the role of mTOR in cancer. Cancer Cell 2007. 12: 9-22.
3. Sarbassov, D. D., Ali, S. M., Kim, D. H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P. et al., Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 2004. 14: 1296-1302.
4. Gorentla, B. K., Wan, C. K. and Zhong, X. P., Negative regulation of mTOR activation by diacylglycerol kinases. Blood 2011. 117: 4022-4031.
5. Salmond, R. J., Emery, J., Okkenhaug, K. and Zamoyska, R., MAPK, phosphatidylinositol 3-kinase, and mammalian target of rapamycin pathways converge at the level of ribosomal protein S6 phosphorylation to control metabolic signaling in CD8 T cells. J. Immunol. 2009. 183: 7388-7397.
6. Zhong, X. P., Shin, J., Gorentla, B. K., O'Brien, T., Srivatsan, S., Xu, L., Chen, Y. et al., Receptor signaling in immune cell development and function. Immunol. Res. 2011. 49: 109-123.
7. Sauer, S., Bruno, L., Hertweck, A., Finlay, D., Leleu, M., Spivakov, M., Knight, Z. A. et al., T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc. Natl. Acad. Sci. USA 2008. 105: 7797-7802.
8. Zheng, Y., Collins, S. L., Lutz, M. A., Allen, A. N., Kole, T. P., Zarek, P. E. and Powell, J. D., A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J. Immunol. 2007. 178: 2163-2170.
9. Delgoffe, G. M., Kole, T. P., Zheng, Y., Zarek, P. E., Matthews, K. L., Xiao, B., Worley, P. F. et al., The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009. 30: 832-844.
10. Lee, K., Gudapati, P., Dragovic, S., Spencer, C., Joyce, S., Killeen, N., Magnuson, M. A. and Boothby, M., Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 2010. 32: 743-753.
11. Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P. et al., mTOR regulates memory CD8 T-cell differentiation. Nature 2009. 460: 108-112.
12. + T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity 2010. 32: 67-78.
13. Sinclair, L. V., Finlay, D., Feijoo, C., Cornish, G. H., Gray, A., Ager, A., Okkenhaug, K. et al., Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat. Immunol. 2008. 9: 513-521.
14. Inoki, K., Li, Y., Zhu, T., Wu, J. and Guan, K. L., TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell. Biol. 2002. 4: 648-657.
15. Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C. and Blenis, J., Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 2003. 13: 1259-1268.
16. Tee, A. R., Fingar, D. C., Manning, B. D., Kwiatkowski, D. J., Cantley, L. C. and Blenis, J., Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl. Acad. Sci. USA 2002. 99: 13571-13576.
17. Kobayashi, T., Minowa, O., Sugitani, Y., Takai, S., Mitani, H., Kobayashi, E., Noda, T. et al., A germ-line TSC1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by TSC2 mutation in mice. Proc. Natl. Acad. Sci. USA 2001. 98: 8762-8767.
18. Chen, C., Liu, Y., Liu, R., Ikenoue, T., Guan, K. L. and Zheng, P., TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J. Exp. Med. 2008. 205: 2397-2408.
19. Thomson, A. W., Turnquist, H. R. and Raimondi, G., Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 2009. 9: 324-337.
20. Gao, X. and Pan, D., TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev. 2001. 15: 1383-1392.
21. Fingar, D. C., Richardson, C. J., Tee, A. R., Cheatham, L., Tsou, C. and Blenis, J., mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 2004. 24: 200-216.
22. Kurokawa, M. and Kornbluth, S., Caspases and kinases in a death grip. Cell 2009. 138: 838-854.
23. Kim, I., Rodriguez-Enriquez, S. and Lemasters, J. J., Selective degradation of mitochondria by mitophagy. Arch. Biochem. Biophys. 2007. 462: 245-253.
24. Pua, H. H., Guo, J., Komatsu, M. and He, Y. W., Autophagy is essential for mitochondrial clearance in mature T lymphocytes. J. Immunol. 2009. 182: 4046-4055.
25. Diaz-Troya, S., Perez-Perez, M. E., Florencio, F. J. and Crespo, J. L., The role of TOR in autophagy regulation from yeast to plants and mammals. Autophagy 2008. 4: 851-865.
26. Mizushima, N., Ohsumi, Y. and Yoshimori, T., Autophagosome formation in mammalian cells. Cell Struct. Funct. 2002. 27: 421-429.
27. Hildeman, D. A., Mitchell, T., Teague, T. K., Henson, P., Day, B. J., Kappler, J. and Marrack, P. C., Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity 1999. 10: 735-744.
28. Jacquel, A., Herrant, M., Legros, L., Belhacene, N., Luciano, F., Pages, G., Hofman, P. et al., Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage. FASEB J. 2003. 17: 2160-2162.
29. Sarbassov, D. D., Guertin, D. A., Ali, S. M. and Sabatini, D. M., Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005. 307: 1098-1101.
30. Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J. et al., Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999. 96: 857-868.
31. Hresko, R. C. and Mueckler, M., mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 2005. 280: 40406-40416.
32. Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y. and Mills, G. B., Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005. 4: 988-1004.
33. Huang, J., Dibble, C. C., Matsuzaki, M. and Manning, B. D., The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol. Cell. Biol. 2008. 28: 4104-4115.
34. Julien, L. A., Carriere, A., Moreau, J. and Roux, P. P., mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol. Cell. Biol. 2010. 30: 908-921.
35. Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J. et al., The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell. Biol. 2004. 166: 213-223.
36. Gonzalez-Rodriguez, A., Alba, J., Zimmerman, V., Kozma, S. C. and Valverde, A. M., S6K1 deficiency protects against apoptosis in hepatocytes. Hepatology 2009. 50: 216-229.
37. Djouder, N., Metzler, S. C., Schmidt, A., Wirbelauer, C., Gstaiger, M., Aebersold, R., Hess, D. et al., S6K1-mediated disassembly of mitochondrial URI/PP1gamma complexes activates a negative feedback program that counters S6K1 survival signaling. Mol. Cell 2007. 28: 28-40.
38. Kwiatkowski, D. J., Zhang, H., Bandura, J. L., Heiberger, K. M., Glogauer, M., el-Hashemite, N. and Onda, H., A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 2002. 11: 525-534.
39. Lee, P. P., Fitzpatrick, D. R., Beard, C., Jessup, H. K., Lehar, S., Makar, K. W., Perez-Melgosa, M. et al., Critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity 2001. 15: 763-774.
40. Zhong, X. P., Hainey, E. A., Olenchock, B. A., Jordan, M. S., Maltzman, J. S., Nichols, K. E., Shen, H. and Koretzky, G. A., Enhanced T cell responses due to diacylglycerol kinase zeta deficiency. Nat. Immunol. 2003. 4: 882-890.